Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | enriched in the midbrain (28 nTPM), where the nigral dopamine neurons sit | 0.90 |
| chemistry Open Targets | compounds already reach it: burosumab | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 5,585 | 0.73 |
| pathways Reactome | 40 pathways; mostly growth signalling | 0.60 |
Knock down and overexpress FGF23 in dopamine neurons; measure phospho-ERK and phospho-AKT response to GDNF and survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils.
- Cell type
- dopamine neurons
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- phospho-ERK and phospho-AKT response to GDNF
- Functional readout
- survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils
- Rule-out
- If neither arm moves phospho-ERK by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of FGF23 in iPSC-derived midbrain dopamine neurons (FOXA2+, LMX1A+, TH+); n = 3 differentiations; readouts: phospho-ERK and phospho-AKT response to GDNF; survival of TH-positive neurons and phospho-α-synuclein (pS129) inclusions after seeding with α-synuclein fibrils. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- FGF23 in dopamine neurons, braak-0.03 (p 0.946) → +0.19 (p 0.623)receipt 10837
Swarm cases
receipt 10837: FGF23 in dopamine neurons, braak
- power
- full sample +0.07 (p 0.794, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.12 (p 0.640, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.05 (p 0.847, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.20, sign flips 3; without severely affected donors +0.07 (p 0.794, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FGF23 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts